Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241215 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome
A Phase 4 study of Myofascial Pain Syndromes and Cervicobrachial Neuralgia, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT00241215 is a Phase 4 study of Myofascial Pain Syndromes and Cervicobrachial Neuralgia that has completed, run by University of California, Los Angeles. The registered enrollment target is 132 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00241215, a Phase 4 study of Myofascial Pain Syndromes and Cervicobrachial Neuralgia, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
Several studies have previously examined the use of botulinum toxin serotype A for myofascial pain of the neck and shoulders (cervicobrachial syndrome). These studies have suffered from: 1. inclusion of confounding conditions in the proband group, and 2. inability to identify predictors of response. This study attempts to define the characteristics of responders to botulinum serotype A for myofascial pain of the neck and shoulders (cervicobrachial syndrome).
Conditions Studied
Interventions
- DRUG Botulinum toxin serotype A
Study Locations (1)
California
- UCLA Pain Management Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2003-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241215
The ClinicalTrials.gov registry entry for NCT00241215 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myofascial Pain Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin serotype A is the first listed.
NCT00241215 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00241215 about?
NCT00241215 is a clinical study titled "Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome". Several studies have previously examined the use of botulinum toxin serotype A for myofascial pain of the neck and shoulders (cervicobrachial syndrome). These studies have suffered from: 1. inclusion of confounding conditions in the proband group, and 2. inability to identify predictors of response...
What is the current status of trial NCT00241215?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 132 participants. The study started on 2003-06.
What conditions does trial NCT00241215 study?
This clinical trial studies the following conditions: Myofascial Pain Syndromes, Cervicobrachial Neuralgia.
What interventions are being tested in trial NCT00241215?
The interventions under investigation include: Botulinum toxin serotype A (DRUG).
Who is sponsoring clinical trial NCT00241215?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00241215 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myofascial Pain Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.